1 / 23

Prof. Giacomo P. Comi

GSD type III: molecular genetics, genotype-phenotype correlations and the project for an animal model. Prof. Giacomo P. Comi

wylie
Télécharger la présentation

Prof. Giacomo P. Comi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GSD type III: molecular genetics, genotype-phenotype correlations and the project for an animal model Prof. Giacomo P. Comi Centro Dino Ferrari,Dipartimento di Scienze NeurologicheUniversità degli Studi di Milano,Fondazione Ospedale Maggiore Policlinico,Mangiagalli e Regina Elena,Milano, Italy

  2. TRANSFERASE DOMAIN GLUCOSIDASE DOMAIN GLYCOGEN-BINDING DOMAIN 1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9 9 10 10 11 11 12 12 13 13 14 14 15 15 16 16 17 17 18 18 19 19 20 20 21 21 22 22 23 23 24 24 25 25 26 26 27 27 28 28 29 29 30 30 31 31 32 32 33 33 34 34 35 35 GLUCOSIDASE DOMAIN TRANSFERASE DOMAIN GLYCOGEN-BINDING DOMAIN GENE AND DISEASE • AGL gene (amylo-1,6-glucosidase, 4-α-glucantransferase) encodes for the glycogen debranching enzyme. • AGL is expressed as a single protein containing two distinct catalytic activities: • 4-α-glucantransferase domain located in the N-terminal half of the protein • 1,6-glucosidase domain in the C-terminal part

  3. Clinical manifestations • Possible infancy and childhood symptoms: • Recurrent fasting hypoglycemia • Seizures • Hepatomegaly • Hypotonus • Growth retardation • Adult symptoms: • Distal weakness (calves and peroneal muscles) • Variable degree of proximal muscles weakness • Fatigue • Back pain • Slow progression • Serum CK increased 5x to 45x • Neuropathy (due to glycogen storage in Schwann cells and axons) • Hepatic dysfunction and cardiomyopathy

  4. Milano Bologna Genova Ancona Firenze Napoli Catania FOCUS ON ITALIAN COHORT OF GSDIII PATIENTS Age at Diagnosis Age Groups

  5. Liver involvement Serum transaminases Liver ecography

  6. Walton score Age Muscle involvement Correlation between CK and age Walton scale

  7. Electromyography was available for 21 patients Pseudo-myotonic discharges at EMG were found in two patients with myopathic findings and in five showing chronic neurogenic denervation

  8. Cardiology Heart echography • Interventricular sept thickness: • normal: <10 mm • mild hypertrophy: 11-12 mm • moderate hypertrophy: 13-14 mm • severe hypertrophy: >14 mm

  9. c.672insT c.700T>C c.753_756delGACA c.757G>C c.3464G>A c.3512_3549dup+3512_3519del c.100G>T c.112A>T c.276delG c. 2023C>T c. 2147delG c. 2929C>T c.3980G>A c.3963delG c.1264A>T c.1283G>A c.3355G>C c.3358G>C c.442delA c.3652C>T ATG TAG c.2681+1G>A 1 3 31 323334 13 14 15 26 27 35 c.853C>T c.3912insA c.2590C>T c.3258_3259 AG>CC c.4193G>A c.4324insA c.293+2T>A c.664+3A>G c.1571G>A c.1589G>C c.2728C>T c.3362+1G>C DNA mutational analysis Glycogen binding domain Glucosidase domain Transferase domain • Mutations are widespread along the whole gene and no hot spot region were found • Private mutations • No mutations were found in exon 3 • Genetic screening of 57 patients: • 38 patients (66,7%): 2 mutations • 7 patients (12,3%): 1 mutation • 12 patients (21%): no mutations

  10. c.672insT c.700T>C c.753_756delGACA c.757G>C c.3464G>A c.3512_3549dup+3512_3519del c.100G>T c.112A>T c.276delG c. 2023C>T c. 2147delG c. 2929C>T c.3980G>A c.3963delG c.1264A>T c.1283G>A c.3355G>C c.3358G>C c.442delA c.3652C>T ATG TAG c.2681+1G>A 1 3 31 323334 13 14 15 26 27 35 c.853C>T c.3912insA c.2590C>T c.3258_3259 AG>CC c.4193G>A c.4324insA c.664+3A>G c.293+2T>A c.1571G>A c.1589G>C c.2728C>T c.3362+1G>C • Mutation analysis: • 39,8% splicing mutations • 24,1% nonsense mutations • 16,9% missense mutations • 9,6% microinsertions • 8,4% microdeletions • 1,2% micro-rearrangements 24,1%: c.2681+1G>A (IVS21 +1 G>A) 10,8%: c.664+3A>G (IVS6 +3 A>G)

  11. Mutations in promoter and intron sequences are missed BUT this kind of mutations and missense mutations request FUNCTIONAL ANALYSIS In vitro models (fibroblast and myoblast) Mutated AGL cDNA Challenging points 1. Molecular screening of the coding sequence and exon-intron junction of AGL gene Feasible for each missense mutation?

  12. Glycogen binding domain Glycosidase domain Trasferasic domain • 4 missense mutations in three different functional domains: • Transferase e glycosidase domain mutations inactivate the specific function of the respective domain and decrease the funtion of the other domain. • Glycogen binding domain mutations impair both binding and enzymatic activities, proabably through an instability at the protein level.

  13. 2. Missense mutations in our cohort account for < 20% of total similar of the findings of other groups working on GSDIII (Goldstein et al., Genet Med 2010) 3. Could it be proper to screen more than 100 control alleles as usual? 4. Enzyme activity assay on red blood cells does not discriminate among the different catalytic functions but avoid patients to undergo liver or muscle biopsy. 5. Genetically undiagnosed patients often lack enzyme activity assay which should come as a first step. Are those patients true GSDIII?

  14. MOUSE MODEL Associazione Italiana Glicogenosi www.genoway.com

  15. MOUSE Agl: locus and gene organization

  16. Different hypothesis for the knock-out model • Constitutive knock-out by deletion of exon 1 containing ATG (corresponding to human exon 3) • The removal of the first ATG should abolish the mRNA translation 2. Constitutive knock-out by deletion of a functional domain The removal of a catalitic domain would not allow the function of the enzyme 3. Tissue-specific or adult-specific “Safe knock-out™” mouse (targeting exon 1) This construct would allow the regular expression of the enzyme until the induction of the Knock-out, which could be tissue specific or time specific, by breeding the chimera with Cre-recombinant strain

  17. Transferase Domain Glucosidase Domain GLYCOGEN-BINDING DOMAIN 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 Deletion of the last 114aa of the glycogen-binding domain (ex 32-34) Evidences that deletions of the C-terminal of the protein abolish both enzymatic activities (Cheng et al., Genes Dev 2007; Cheng et al., Hum Mol Genet 2009) Criteria for the choice of the best mouse model • We need a model reproducing the human disease • AGL is expressed in many tissues • Mutations do not seem to affect fertility and fetal development Constitutive knock-out model

  18. Constitutive knock-out model by deletion of the glycogen-binding domain: targeting vector

  19. Constitutive knock-out model by deletion of the glycogen-binding domain

  20. Testing mouse to better understand • Diet treatment: composition and relation with age • Physical exercise and metabolism • Peripheral nerve involvement • Glycogen deposition vs musculoskeletal impairment …and more A good mouse model would allow the development of potential drugs and Enzyme Replacement Therapy

  21. Thanks to • Patients • Physicians • Associazione Italiana Glicogenosi

  22. In collaboration with: Istituto G. Gaslini, Genova: Mirella Filocamo, Maja Di Rocco Università degli Studi, Catania: Agata Fiumara Ist. Pediatrico, Univ. Federico II, Napoli: Daniela Melis Ospedale S. Gerardo, Monza: Rossella Parini Pediatria Ospedale San Paolo, Milano: Sabrina Paci Ospedale Pediatrico Meyer, Firenze: Maria Alice Donati Università di Pisa: Giuseppe Maggiore Università Politecnica delle Marche: Anna Ficcadenti Ospedale S. Orsola-Malpighi, Bologna: Monia Gennari Università degli Studi, Padova: Corrado Angelini Dipartimento di Neuroscienze, Messina: Giuseppe Vita, Antonio Toscano

  23. Laboratorio di Biochimica e Genetica Dip. di Scienze Neurologiche Giacomo P. Comi Stefania Corti Sabrina Lucchiari Monica Nizzardo Serena Pagliarani Serena Ghezzi Dario Ronchi Sabrina Salani Chiara Donadoni Martina Nardini Elisa Fassone Francesco Fortunato Andreina Bordoni Roberto Del Bo Domenica Saccomanno Gianna Ulzi Alessio Di Fonzo Isabella Ghione Domenico Santoro Francesca Magri Alessandra Govoni Michela Ranieri

More Related